29
Participants
Start Date
December 16, 2024
Primary Completion Date
June 30, 2028
Study Completion Date
July 31, 2028
Azacitidine (AZA)
"Dosing is 75 mg/m2 x 7 days (Q28days) After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
Venetoclax
"Dosing: 400 mg daily After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
RECRUITING
Institut Catala D oncologia Girona, Girona
RECRUITING
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida, Lleida
RECRUITING
Hospital General Universitario Gregorio Maranon, Madrid
RECRUITING
Hospital Universitari Joan XXIII De Tarragona, Tarragona
RECRUITING
Hospital Clinico Universitario De Valencia, Valencia
RECRUITING
University Hospital Son Espases, Palma de Mallorca
RECRUITING
Hospital Son Llatzer, Palma de Mallorca
RECRUITING
Institut Catala D oncologia Badalona, Badalona
RECRUITING
Hospital Del Mar, Barcelona
RECRUITING
Hospital De La Santa Creu I Sant Pau, Barcelona
RECRUITING
Hospital Universitari Vall D Hebron, Barcelona
RECRUITING
Hospital Clinic De Barcelona, Barcelona
RECRUITING
Institut Catala D oncologia Hospitalet, L'Hospitalet de Llobregat
RECRUITING
Fundacio Assistencial De Mutua De Terrassa, Terrassa
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
OTHER